Polypid Ltd

NASDAQ:PYPD   3:33:56 PM EDT
1.12
+0.03 (+2.75%)
Regulatory, Earnings Announcements

Polypid Announces Mid-Stage Study Results For D-Plex₁₀₀

Published: 09/19/2022 11:12 GMT
Polypid Ltd (PYPD) - Polypid Announces Peer-reviewed Publication of Phase 2 Clinical Trial Results for D-plex₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery.
Polypid Announces Peer-reviewed Publication of Phase 2 Clinical Trial Results for D-plex₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery.
Polypid - Intends to Discuss Clinical Outcomes and Next Steps for D-plex100 for Prevention of Ssis in Abdominal Surgery With FDA and Eu in Q1 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.61

More details on our Analysts Page.